Actively Recruiting
Calprotectine in Spondyloarthritis
Led by Centre Hospitalier Universitaire de Nice · Updated on 2024-05-17
190
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology
CONDITIONS
Official Title
Calprotectine in Spondyloarthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients under active care in the rheumatology department with one of the following: active spondyloarthritis (BASDAI >4), spondyloarthritis in low activity (BASDAI <4), fibromyalgia without inflammatory rheumatism, or healthy subjects without inflammatory rheumatism or fibromyalgia
- Patients who have not objected to the use of their samples
- Affiliated with the social security system
You will not qualify if you...
- Minor patients
- Subjects not affiliated with the social security system
- Subjects deprived of liberty
- Patients under guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nice University Hospital
Nice, France, 06000
Actively Recruiting
Research Team
C
Christian ROUX, PUPH
CONTACT
J
Jeremy GENOVESE
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here